Lung diseases are a major global health concern. Many conditions begin silently with subtle signs. Early detection of ...

A new study reports that a routine, low-cost nutritional assessment tool may offer a powerful way to predict survival in patients with progressive pulmonary fibrosis (PPF), a life-shortening condition ...

For millions of people with COPD, asthma, or lung damage after tuberculosis, the impact of a preventive injection may be a ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, ...

As respiratory virus season begins, pediatric experts are preparing for an expected rise in cases of Respiratory Syncytial ...

Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM ESTCompany ParticipantsTony Wood - Chief Scientific Officer and Head ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

The full research report is available Bioxytran is considered a speculative investment, yet significantly de-risked due to its strong galectin science and robust clinical efficacy demonstrated in ...

Good morning, and welcome to the Jefferies 2025 Healthcare Conference. It's my pleasure now to introduce David Kirn, CEO; and Chris Simms, Chief Commercial Officer of 4D Molecular Therapeutics. All ...